Cytogenetics of pediatric acute myeloid leukemia, Eur J Haematol, vol.83, issue.5, pp.391-405, 2009. ,
Place de la cytoge?ne?tique dans la prise en charge des leuce?mies aiguës mye?loïdes : actualisation par le Groupe francophone de cytogénétique hématologique (GFCH), Ann Biol Clin (Paris). 1 sept, vol.74, issue.5, pp.535-581, 2016. ,
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia, N Engl J Med. 11 juill, vol.369, issue.2, pp.111-132, 2013. ,
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, Blood, vol.19, issue.20, pp.2391-405, 2016. ,
The Differentiation Syndrome in Patients with Acute Promyelocytic Leukemia: Experience of the Pethema Group and Review of the ,
, Mediterr J Hematol Infect Dis, vol.4, issue.2011
,
Management of patients with acute promyelocytic leukemia, Leukemia. juin, vol.32, issue.6, pp.1277-94, 2018. ,
First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid. Pediatr Blood Cancer, vol.64, 2017. ,
GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children, Blood. 15 juill, vol.106, issue.2, pp.447-53, 2005. ,
Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group, J Clin Oncol Off J Am Soc Clin Oncol, vol.23, issue.30, pp.7632-7672, 2005. ,
,
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes, Blood. 30 juill, vol.114, issue.5, pp.937-51, 2009. ,
Acute myeloblastic leukaemias and myelodysplastic syndromes in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol Off J Eur Soc Med Oncol. mai, vol.21, issue.5, pp.158-161, 2010. ,
Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patients, Br J Haematol. janv, vol.86, issue.1, pp.82-91, 1994. ,
, , 2010.
,
Incidence of cancer in children in the ,
, Sex-, race-, and 1-year age-specific rates by histologic type, Cancer. 15 avr, vol.75, issue.8, pp.2186-95, 1995.
, , 2005.
Utilisations thérapeutiques des facteurs de croissance hématopoïétiques. I. Erythropoïétine et thrombopoïétine, Ann Biol Clin (Paris). 26 mars, vol.56, issue.2, pp.143-52, 1998. ,
Hématopoïèse et facteurs de croissance, pp.13-16906 ,
,
Histologie et biologie cellulaire: Une introduction à l'anatomie pathologique. De Boeck Supérieur, vol.648, 2006. ,
Utilisation des facteurs de croissance hématopoïétiques: guide pratique ,
, , 1996.
Acute myeloid leukemia originates from a hierarchy of ,
The molecular basis of leukemia, Hematol Am Soc Hematol Educ Program, pp.80-97, 2004. ,
Environmental and genetic risk factors for childhood leukemia: appraising the evidence, Cancer Invest, vol.23, issue.1, pp.60-75, 2005. ,
Evidence for an infective cause of childhood leukaemia: comparison of a Scottish new town with nuclear reprocessing sites in Britain. The Lancet, vol.10, pp.1323-1330, 1988. ,
Infection, immune responses and the aetiology of childhood leukaemia ,
, Nat Rev Cancer. mars, vol.6, issue.3, pp.193-203, 2006.
Infections in early life and risk of childhood ALL, Br J Cancer. 10 mars, vol.100, issue.5, p.863, 2009. ,
Childhood acute leukemia, early common infections, and allergy: The ESCALE Study, Am J Epidemiol, vol.172, issue.9, pp.1015-1042, 2010. ,
,
, Early life exposure to infections and risk of childhood acute lymphoblastic leukemia, Int J Cancer. 1 avr, vol.128, issue.7, pp.1632-1675, 2011.
Risk Factors for Acute Leukemia in Children: A Review. Environ Health Perspect, janv, vol.115, issue.1, pp.138-183, 2007. ,
, Residential Pesticides and Childhood Leukemia
, A Systematic Review and Meta-Analysis. Environ Health Perspect. janv, vol.118, issue.1, pp.33-41, 2010.
,
, Household exposure to pesticides and risk of childhood hematopoietic malignancies: The ESCALE study (SFCE). Environ Health Perspect, déc, vol.115, issue.12, pp.1787-93, 2007.
, Utero, and Early-Life Exposure to Benzene and the Risk of Childhood Leukemia: A Meta-Analysis
, Am J Epidemiol. 1 janv, vol.183, issue.1, pp.1-14, 2016.
Road Traffic and Childhood Leukemia: The ESCALE Study (SFCE), Environ Health Perspect. avr, vol.119, issue.4, pp.566-72, 2011. ,
Risk of Childhood Cancer and Socio-economic Disparities: Results of the French Nationwide Study Geocap, Paediatr Perinat Epidemiol, vol.30, issue.6, pp.612-634, 2002. ,
Parental smoking, maternal alcohol, coffee and tea consumption during pregnancy, and childhood acute leukemia: the ESTELLE study, Cancer Causes Control CCC. juill, vol.26, issue.7, pp.1003-1020, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01175534
Acute Myeloid Leukemia, N Engl J Med, vol.30 ,
URL : https://hal.archives-ouvertes.fr/hal-02143595
, sept, vol.341, issue.14, pp.1051-62, 1999.
,
, Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet, Blood. 21 janv, vol.115, issue.3, pp.453-74, 2010.
,
, Proposals for the classification of the acute leukaemias. French-American-British (FAB) cooperative group, Br J Haematol. août, vol.33, issue.4, pp.451-459, 1976.
,
, Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group, Ann Intern Med. oct, vol.103, issue.4, pp.620-625, 1985.
,
, The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues, Ann Oncol Off J Eur Soc Med Oncol. déc, vol.10, issue.12, pp.1419-1451, 1997.
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, Blood, vol.19, issue.20, pp.2391-405, 2016. ,
,
Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia, Blood. août, vol.72, issue.2, pp.567-72, 1988. ,
Alltrans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationship, Blood, vol.76, issue.9, pp.1710-1717, 1990. ,
Histoire(s) de la leucémie aiguë, Rev Prat, vol.65, p.5, 2015. ,
United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia, J Clin Oncol Off J Am Soc Clin Oncol. 15 sept, vol.19, issue.18, pp.3852-60, 2001. ,
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia ,
, Engl J Med. 11 juill, vol.369, issue.2, pp.111-132, 2013.
Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients, Blood, vol.15, issue.10, pp.3315-3339, 1999. ,
Management of relapsed and refractory childhood acute promyelocytic leukaemia: recommendations from an international expert panel, Br J Haematol, vol.175, issue.4, pp.588-601, 2016. ,
,
, APL): Comparison Between Children and Adults, Mediterr J Hematol Infect Dis
Epidemiology, diagnosis and treatment of acute promyelocytic leukemia in children: the experience in china, Mediterr J Hematol Infect Dis, vol.4, issue.1, p.2012012, 2012. ,
Retrospective study of arsenic trioxide for childhood acute promyelocytic leukemia in China: a single-center experience, Int J Hematol. juin, vol.91, issue.5, pp.820-825, 2010. ,
Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia, Blood. 4 mars, vol.115, issue.9, pp.1697-702, 2010. ,
Effect of arsenic trioxide on the treatment of children with newly diagnosed acute promyelocytic leukemia in China, Int J Hematol. févr, vol.93, issue.2, pp.199-205, 2011. ,
Long-term prognosis of childhood ,
La leuce?mie aiguë promylocytaire : un paradigme des traitements cible?s sur l'oncogène ?, MS Me?decine Sci Rev Pap ISSN, p.767 ,
DOI : 10.4267/10608/1783
,
,
, PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1, J Cell Biol, vol.147, issue.2, pp.221-255, 1999.
PML induces a novel caspase-independent death process, Nat Genet, vol.20, issue.3, pp.259-65, 1998. ,
Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide, N Engl J Med, vol.339, pp.1341-1349, 1998. ,
Arsenicinduced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia, Proc Natl Acad Sci U S A. 15 avr, vol.94, issue.8, pp.3978-83, 1997. ,
Human Daxx regulates Fas-induced apoptosis from nuclear PML oncogenic domains (PODs), EMBO J, vol.18, issue.21, pp.6037-6086, 1999. ,
DOI : 10.1093/emboj/18.21.6037
URL : http://emboj.embopress.org/content/18/21/6037.full.pdf
,
, Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells, Blood. 1 juin, vol.91, issue.11, pp.4300-4310, 1998.
Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy, J Clin Oncol Off J Am Soc Clin Oncol. 15 avr, vol.22, issue.8, pp.1404-1416, 2004. ,
First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standardrisk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid ,
, Pediatr Blood Cancer. août, vol.64, issue.8, 2017.
, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia, survival, vol.15, issue.11, pp.1525-1533, 2016.
Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data, J Clin Oncol Off J Am Soc Clin Oncol. 20 août, vol.28, issue.24, pp.3866-71, 2010. ,
,
, Fatigue as an important aspect of quality of life in patients with acute myeloid leukemia, Leuk Res. avr, vol.26, issue.4, pp.355-62, 2002.
,
, Randomized Phase III Trial of Retinoic Acid and Arsenic Trioxide Versus Retinoic Acid and Chemotherapy in Patients With Acute Promyelocytic Leukemia: Health-Related Quality-ofLife Outcomes, J Clin Oncol, vol.32, issue.30, pp.3406-3418, 2014.
Effectivity of a modified Sanz risk model for early death prediction in patients with newly diagnosed acute promyelocytic leukemia, Ann Hematol, vol.96, issue.11, pp.1793-800, 2017. ,
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, Lancet Oncol, vol.16, issue.13, pp.1295-305, 2015. ,